{
    "cancer_info": {
        "cancer_name": "Dermatofibrosarcoma Protuberans (DFSP)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and physical examination (H&P) with complete skin exam",
            "Punch/incisional/core biopsy including subcutaneous layer",
            "Re-biopsy if indeterminate or clinical suspicion persists",
            "Pathology with H&E staining and immunohistochemistry (CD34+, factor XIIIa-)",
            "FISH or PCR for COL1A1-PDGFB fusion if equivocal",
            "Preoperative MRI with contrast if extensive subcutaneous extension suspected",
            "Multidisciplinary consultation for large/recurrent tumors"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Primary (localized) disease",
            "risk_group": "Standard DFSP (low metastatic risk <5%)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary therapy",
                    "patient_subgroup": "All resectable cases",
                    "plan_name": "Surgical resection with PDEMA",
                    "plan_details": "Mohs micrographic surgery or peripheral/deep en face margin assessment preferred. Wide local excision only if PDEMA unavailable. Delay reconstruction until margins confirmed clear.",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                },
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Positive/narrow margins when re-resection impossible",
                    "plan_name": "Radiation therapy",
                    "plan_details": "50-66 Gy in 2-Gy fractions. Fields extend 3-5 cm beyond surgical margins",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                },
                {
                    "treatment_line": "Neoadjuvant therapy",
                    "patient_subgroup": "Unresectable/borderline resectable disease",
                    "plan_name": "Imatinib",
                    "plan_details": "Confirm PDGFB translocation via FISH prior to administration. Used to preserve function/cosmesis",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        },
        {
            "staging_criteria": "Primary (localized) disease",
            "risk_group": "FS-DFSP (high metastatic risk 15-20%)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary therapy",
                    "patient_subgroup": "All cases",
                    "plan_name": "Referral to sarcoma center",
                    "plan_details": "Multidisciplinary management due to increased metastatic risk",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                },
                {
                    "treatment_line": "Surveillance",
                    "patient_subgroup": "Post-treatment monitoring",
                    "plan_name": "CT imaging",
                    "plan_details": "CT of draining nodal basin and chest per Soft Tissue Sarcoma guidelines",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        },
        {
            "staging_criteria": "Recurrent or metastatic disease",
            "risk_group": "All",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Local recurrence",
                    "plan_name": "Re-resection ± RT",
                    "plan_details": "Surgical re-excision with radiation therapy if not previously administered",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Unresectable/metastatic PDGFB-positive tumors",
                    "plan_name": "Imatinib",
                    "plan_details": "PDGFR inhibitor targeted therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                },
                {
                    "treatment_line": "Symptom management",
                    "patient_subgroup": "When surgery impossible",
                    "plan_name": "Radiation therapy",
                    "plan_details": "For symptomatic control",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                },
                {
                    "treatment_line": "Management",
                    "patient_subgroup": "Metastatic cases",
                    "plan_name": "Multidisciplinary consultation",
                    "plan_details": "Mandatory referral to sarcoma center per Soft Tissue Sarcoma guidelines",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Appropriate"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "CD34 immunopositivity: Diagnostic hallmark (lost during fibrosarcomatous transformation)",
            "COL1A1-PDGFB fusion: Diagnostic confirmation (>90% prevalence) and therapeutic predictor of imatinib response",
            "FS-DFSP markers: High cellularity, herringbone pattern, mitotic activity (>5-10/HPF) indicate fibrosarcomatous transformation"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：隆突性皮肤纤维肉瘤.txt"
}